|By PR Newswire||
|April 23, 2014 02:30 PM EDT||
SEATTLE, April 23, 2014 /PRNewswire-USNewswire/ -- TB Alliance, an international non-profit drug development organization that develops better, faster-acting, and affordable tuberculosis (TB) drugs, has announced that it is collaborating with, and has granted an exclusive license to, the Shanghai Fosun Pharmaceutical Development Co., Ltd., and its subsidiary Shenyang Hongqi Pharmaceutical Co., Ltd. (Fosun Pharma), to develop and commercialize the first-ever regimen designed to treat both drug-sensitive TB (DS-TB) and multi-drug resistant TB (MDR-TB) for use within People's Republic of China, Taiwan, Hong Kong and Macau (Licensed Territory).
PaMZ, a novel TB drug regimen, shows the potential to be a shorter, simpler, safer and affordable treatment for both DS-TB and some forms of MDR-TB. The regimen has reached a major milestone and is now ready to enter a global Phase 3 clinical trial. Shenyang Hongqi Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Fosun Pharma, is the largest manufacturer and distributor of TB treatments in China. The collaboration, announced today at the Global Health Product Development Forum, organized by the Bill & Melinda Gates Foundation, in Seattle, Washington, is important to help expedite the final stage of clinical development and, if successful, ensure that the promising PaMZ treatment is made available in the Licensed Territory to the people who need it.
"This collaboration is emblematic of the type of innovative partnerships needed to truly advance global health technologies," said Mel Spigelman, MD, president and CEO of TB Alliance. "Through this partnership, Fosun Pharma will both help support the global registration of urgently needed new tools for TB, while also retaining the benefits of a traditional product developer within their core market; this is the sort of agreement that product development partnerships are able to achieve to benefit the millions of patients needlessly dying from neglected diseases of poverty such as TB."
According to a report from the National Health and Family Planning Commission of the People's Republic of China, the country has the world's second largest TB epidemic, including MDR-TB, as each year, approximately one million people in the country contract the disease, with 50,000 of those cases estimated to be MDR-TB. New TB treatments are urgently needed. Currently, people with MDR-TB require a minimum of 18 to 24 months of treatment, with thousands of costly pills and daily injections for the first six months of therapy. MDR-TB treatment is cost-prohibitive for many MDR-TB patients and health systems, severely limiting the number of patients who even receive any treatment.
Under this agreement, Fosun Pharma will support research sites in the People's Republic of China as part of the newly announced Phase 3 STAND (Shortening TB Treatment by Advancing Novel Drugs) trial and will conduct any additional studies required for regulatory approval of PaMZ in the Licensed Territory. If the regimen is successful, Fosun Pharma will commercialize the PaMZ regimen in the Licensed Territory. As part of the terms of the agreement, the company has committed to the principles of affordability and accessibility for the treatment.
"TB is a significant issue in our country and there remains a critical need for new and improved tools to overcome the disease," said Mr. Qiyu Chen, chairman of Fosun Pharma. "We are proud to take a lead role in the fight against TB and contribute to the development of this promising new treatment."
PaMZ consists of two new drug candidates, PA-824 and moxifloxacin, and pyrazinamide, part of the current first-line treatment. Earlier studies show PaMZ's potential to treat both DS-TB and MDR-TB patients with the same oral therapy, and to shorten treatment, especially for those with MDR-TB. The development of PaMZ is projected to save years of time by testing new drugs simultaneously as a "drug regimen," instead of one-by-one. In July 2012, a two-week study published in The Lancet showed that PaMZ appeared to kill patients' bacteria more quickly than standard therapy after starting treatment.
If successful, the regimen would eliminate the need for injectable drugs and significantly reduce the cost of MDR-TB therapy, in some countries by more than 90 percent, in those patients whose TB organisms are sensitive to the three drugs. It also promises to be compatible with commonly used HIV drugs, helping the millions of people co-infected with TB/HIV.
About TB Alliance (Global Alliance for TB Drug Development)
TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. The TB Alliance operates with funding from Bill & Melinda Gates Foundation, Department of Foreign Affairs and Trade, Department for International Development (DFID), European Commission (DFAT), Global Health Innovative Technology Fund (GHIT Fund), Irish Aid, National Institute of Allergy and Infectious Disease (NIAID), UNITAID, United States Agency for International Development (USAID) and the United States Food and Drug Administration (FDA). For more information please visit tballiance.org.
About Fosun Pharma
Established in 1994, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) is a leading healthcare company in China, which was listed on Shanghai Stock Exchange in August 1998 and on the Main Board of the Stock Exchange of Hong Kong Limited in October 2012 (stock code: 600196-SH, 02196-HK). Specializing in modern biopharmaceutical and healthcare industry, our main businesses include pharmaceutical manufacturing, pharmaceutical distribution and retail, healthcare services, medical diagnosis and medical devices. With its commitment to innovation for good health, Fosun Pharma aims to become the first-tier enterprise in the global mainstream pharmaceutical and healthcare market. Shenyang Hongqi Pharmaceutical Co., Ltd., a wholly-owned subsidiary of Fosun Pharma, has been the largest manufacturer and distributor of TB treatments for over 30 years in China. For more information on Fosun Pharma, please visit www.fosunpharma.com.
For more information, please contact:
Preeti Singh at +1-(301) 280-5722 or [email protected]
SOURCE TB Alliance
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, will discuss the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports. The session will include a working demo and a technical d...
Sep. 25, 2016 10:00 PM EDT Reads: 1,690
SYS-CON Events announced today that Commvault, a global leader in enterprise data protection and information management, has been named “Bronze Sponsor” of SYS-CON's 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Commvault is a leading provider of data protection and information management solutions, helping companies worldwide activate their data to drive more value and business insight and to transform moder...
Sep. 25, 2016 09:30 PM EDT Reads: 2,471
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace.
Sep. 25, 2016 09:00 PM EDT Reads: 909
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
Sep. 25, 2016 08:30 PM EDT Reads: 4,397
SYS-CON Events announced today that Bsquare has been named “Silver Sponsor” of SYS-CON's @ThingsExpo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. For more than two decades, Bsquare has helped its customers extract business value from a broad array of physical assets by making them intelligent, connecting them, and using the data they generate to optimize business processes.
Sep. 25, 2016 07:30 PM EDT Reads: 2,584
I'm a lonely sensor. I spend all day telling the world how I'm feeling, but none of the other sensors seem to care. I want to be connected. I want to build relationships with other sensors to be more useful for my human. I want my human to understand that when my friends next door are too hot for a while, I'll soon be flaming. And when all my friends go outside without me, I may be left behind. Don't just log my data; use the relationship graph. In his session at @ThingsExpo, Ryan Boyd, Engi...
Sep. 25, 2016 07:15 PM EDT Reads: 1,236
SYS-CON Events announced today that Pulzze Systems will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Pulzze Systems, Inc. provides infrastructure products for the Internet of Things to enable any connected device and system to carry out matched operations without programming. For more information, visit http://www.pulzzesystems.com.
Sep. 25, 2016 06:30 PM EDT Reads: 1,809
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
Sep. 25, 2016 05:30 PM EDT Reads: 1,552
SYS-CON Events announced today that Secure Channels will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. The bedrock of Secure Channels Technology is a uniquely modified and enhanced process based on superencipherment. Superencipherment is the process of encrypting an already encrypted message one or more times, either using the same or a different algorithm.
Sep. 25, 2016 05:15 PM EDT Reads: 1,529
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
Sep. 25, 2016 05:00 PM EDT Reads: 1,758
Almost two-thirds of companies either have or soon will have IoT as the backbone of their business in 2016. However, IoT is far more complex than most firms expected. How can you not get trapped in the pitfalls? In his session at @ThingsExpo, Tony Shan, a renowned visionary and thought leader, will introduce a holistic method of IoTification, which is the process of IoTifying the existing technology and business models to adopt and leverage IoT. He will drill down to the components in this fra...
Sep. 25, 2016 03:00 PM EDT Reads: 1,582
The vision of a connected smart home is becoming reality with the application of integrated wireless technologies in devices and appliances. The use of standardized and TCP/IP networked wireless technologies in line-powered and battery operated sensors and controls has led to the adoption of radios in the 2.4GHz band, including Wi-Fi, BT/BLE and 802.15.4 applied ZigBee and Thread. This is driving the need for robust wireless coexistence for multiple radios to ensure throughput performance and th...
Sep. 25, 2016 02:30 PM EDT Reads: 1,525
Enterprise IT has been in the era of Hybrid Cloud for some time now. But it seems most conversations about Hybrid are focused on integrating AWS, Microsoft Azure, or Google ECM into existing on-premises systems. Where is all the Private Cloud? What do technology providers need to do to make their offerings more compelling? How should enterprise IT executives and buyers define their focus, needs, and roadmap, and communicate that clearly to the providers?
Sep. 25, 2016 02:00 PM EDT Reads: 1,522
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...
Sep. 25, 2016 02:00 PM EDT Reads: 2,612
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Sep. 25, 2016 01:00 PM EDT Reads: 838